GSK
1 year ago ⋅ English ⋅ 3 min read
Newsroom
GSK announces positive results from DREAMM-8 phase III trial for Blenrep versus standard of care combination in relapsed/refractory multiple myeloma

For media and investors only- Trial unblinded early at an interim analysis based on Independent Data Monitoring Committee recommendation- Blenrep (belantamab mafodotin) plus PomDex show... Read More
GSK
1 year ago ⋅ English ⋅ 4 min read
Newsroom
ViiV Healthcare announces interim data at CROI indicating superior efficacy of long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) compared to daily oral therapy in individuals living with HIV who have adherence challenges

For media and investors onlyViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced data from a... Read More
GSK
1 year ago ⋅ English ⋅ 4 min read
Newsroom
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses

For media and investors only- Data show for the first time a new ultra long-acting cabotegravir formulation (CAB-ULA) that doubles the current dosing interval- Pharmacokinetic, tolerabi... Read More
GSK
1 year ago ⋅ English ⋅ 3 min read
Newsroom
GSK announces Dr Jeannie Lee to join the Board as Non-Executive Director

For media and investors onlyGSK plc (LSE/NYSE: GSK) has today announced that Dr Jeannie Lee has been appointed to the Board of the Company as a Non-Executive Director. Jeannie will join... Read More
GSK
1 year ago ⋅ English ⋅ 1 min read
Newsroom
Statement: Zantac (ranitidine) litigation

For media and investors onlyGSK plc (LSE/NYSE: GSK) today confirmed it has reached a confidential settlement with Boyd/Steenvoord, resolving the case filed in California state court. Th... Read More
GSK
1 year ago ⋅ English ⋅ 8 min read
Newsroom
ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV

For media and investors only- Other key data to be presented from ViiV Healthcare’s innovative pipeline and portfolio include the exploration of different mechanisms of action thr... Read More